ASCO 2024 | Racial inequities in breast cancer outcomes and tumor biology in RxPONDER

Yara Abdou, MD, UNC School of Medicine, Chapel Hill, NC, discusses racial disparities in breast cancer outcomes as examined in the RxPONDER trial (NCT01272037). Gene axes scores were determined by an assay consisting of 16 cancer-related genes. Non-Hispanic Black women had higher proliferation scores, while Asians had higher HER2 scores. The analysis revealed that racial differences in gene expression contribute to varying outcomes. These findings highlight the importance of understanding tumor biology to address disparities in breast cancer treatment and outcomes. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.